IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coppens, I.
Right arrow Articles by Locht, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coppens, I.
Right arrow Articles by Locht, C.

Infection and Immunity, September 2001, p. 5440-5446, Vol. 69, No. 9
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.9.5440-5446.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Production of Neisseria meningitidis Transferrin-Binding Protein B by Recombinant Bordetella pertussis

Isabelle Coppens,1,dagger Sylvie Alonso,1 Rudy Antoine,1 Françoise Jacob-Dubuisson,1 Geneviève Renauld-Mongénie,2 Eric Jacobs,3 and Camille Locht1,*

Laboratoire de Microbiologie Génétique et Moléculaire, INSERM U447, Institut Pasteur de Lille, F-59019 Lille,1 Aventis-Pasteur, F-69280 Marcy-l'Etoile,2 and Transgène, F-67082 Strasbourg,3 France

Received 12 April 2001/Returned for modification 11 May 2001/Accepted 18 June 2001

Neisseria meningitidis serogroup B infections are among the major causes of fulminant septicemia and meningitis, especially severe in young children, and no broad vaccine is available yet. Because of poor immunogenicity of the serogroup B capsule, many efforts are now devoted to the identification of protective protein antigens. Among those are PorA and, more recently, transferrin-binding protein B (TbpB). In this study, TbpB of N. meningitidis was genetically fused to the N-terminal domain of the Bordetella pertussis filamentous hemagglutinin (FHA), and the fha-tbpB hybrid gene was expressed in B. pertussis either as a plasmid-borne gene or as a single copy inserted into the chromosome. The hybrid protein was efficiently secreted by the recombinant strains, despite its large size, and was recognized by both anti-FHA and anti-TbpB antibodies. A single intranasal administration of recombinant virulent or pertussis-toxin-deficient, attenuated B. pertussis to mice resulted in the production of antigen-specific systemic immunoglobulin G (IgG), as well as local IgG and IgA. The anti-TbpB serum antibodies were of the IgG1, IgG2a, and IgG2b isotypes and were found to express complement-mediated bactericidal activity against N. meningitidis. These observations indicate that recombinant B. pertussis may be a promising vector for the development of a mucosal vaccine against serogroup B meningococci.


* Corresponding author. Mailing address: Laboratoire de Microbiologie Génétique et Moléculaire, INSERM U447, Institut Pasteur de Lille, 1 rue du Prof. Calmette, F-59019 Lille Cedex, France. Phone: (33) 3.20.87.11.51. Fax: (33) 3.20.87.11.58. E-mail: camille.locht{at}pasteur-lille.fr.

dagger Present address: Laboratory of Clinical Investigation, School of Medicine, Yale University, New Haven, CT 06520-8022.


Infection and Immunity, September 2001, p. 5440-5446, Vol. 69, No. 9
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.9.5440-5446.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2001 by the American Society for Microbiology. All rights reserved.